Tag

Merck

9 stories

Deals Jul 6, 2026

Novartis Buys Myricx for $1.1B in ADC Push

Novartis just paid $1.1B for a biotech whose lead drugs have never touched a human patient. The math on that bet doesn't look cheap.

Deals Apr 27, 2026

Sun Pharma Bought Organon for $11.75B, Debt Included

Sun Pharma paid $11.75 billion, or $14 a share in cash, to buy Organon in a deal that positions the India-based generics maker among the world's biosimilar…

FDA Apr 18, 2026

Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3

Merck's MK-2010 posted a 55% unconfirmed overall response rate among 11 previously untreated PD-L1-positive non-small cell lung cancer patients, the first…

Deals Apr 15, 2026

Bain Built $300M Beeline Medicines on 5 BMS Autoimmune Programs

Bain Capital put $300 million into Beeline Medicines at launch, licensing five autoimmune programs from Bristol Myers Squibb to build its next specialty…

FDA Apr 14, 2026

IDEAYA Files FDA: Darovasertib Doubles PFS to 6.9 Months

Darovasertib, IDEAYA Biosciences and Servier's PKC inhibitor for metastatic uveal melanoma, more than doubled median progression-free survival in its Phase…

Deals Apr 9, 2026

Paid $20M Upfront, Roche Extends C4T Molecular Glue Deal

Roche is paying $20 million upfront for access to two degrader-antibody conjugate (DAC) programs from C4 Therapeutics, with more than $1 billion in…

FDA Apr 8, 2026

Merck Reworks Zhifei China Vaccine Deal

Merck renegotiated its China vaccine supply agreement with distribution partner Zhifei.

Deals Apr 8, 2026

Merck Cut Terns Bid by $1B After Leukemia Data Missed

Merck cut its Terns offer from $7.7B to $6.7B after Phase 1 leukemia data disappointed. The rival bidder walked entirely.

Deals Apr 7, 2026

Lilly Bets on Orexins, Tirzepatide Playbook Repeats

Eli Lilly acquires into the orexin drug class, betting the maturing CNS mechanism follows the same multi-indication arc as GLP-1.